1-13 of 13
Rory Michael Shallis
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Second Malignancies Among Older Patients with Classical Myeloproliferative Neoplasms Treated with Ruxolitinib

Jessica M. Stempel, Rong Wang, Rory Michael Shallis, Scott F. Huntington, Amer M. Zeidan, Natalia Neparidze, Mengyang Di, Xiaomei Ma, Nikolai A. Podoltsev
Journal: Blood
Blood (2022) 140 (Supplement 1): 11004–11006.
https://doi.org/10.1182/blood-2022-165156
Published: 2022
Journal Articles

Predictors of Long-Term Outcome in TP53 -Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Talha Badar, Ehab L. Atallah, Rory Michael Shallis, Antoine N. Saliba, Maximilian F. Stahl, Jan Philipp Bewersdorf, Justin Grenet, Anand Ashwin Patel, Yasmin Abaza, Guru Subramanian Guru Murthy, Adam S Duvall, Madelyn Burkart, Neil Palmisiano, Michal Jakub Kubiak, Vamsi K. Kota, Shira Dinner, Aaron D Goldberg, Mark R. Litzow
Journal: Blood
Blood (2022) 140 (Supplement 1): 1435–1437.
https://doi.org/10.1182/blood-2022-167731
Published: 2022
Journal Articles

Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITD high but Not FLT3-ITD low and FLT3-TKD and Role of Transplant in Patients over 60 Years of Age

Eric S. Winer, Yael Flamand, Rory Michael Shallis, Jessica M. Stempel, Aaron D Goldberg, Maximilian F. Stahl, Anand Ashwin Patel, Adam S Duvall, Yasmin Abaza, Timothy Seijung Oh, Karen Ma, Talha Badar, Mark R. Litzow, Vamsi Kota, Danielle Bradshaw, Hari S. Raman, Marlise R. Luskin, Richard M. Stone, Daniel J. DeAngelo
Journal: Blood
Blood (2022) 140 (Supplement 1): 6285–6287.
https://doi.org/10.1182/blood-2022-170587
Published: 2022
Journal Articles

Feasibility and Safety of Outpatient Hypomethylating Agent (HMA) + Venetoclax (Ven) Initiation +/- Ramp-up for Patients (pts) with Newly-Diagnosed Acute Myeloid Leukemia (AML)

Rory Michael Shallis, Julian Weiss, Eric S. Winer, Talha Badar, Alok Swaroop, Peter Doukas, Emily Geramita, Henry Le, Sonal Agarwal, Man Yee Merl, Annie Im, Yasmin Abaza, Mark R. Litzow, Nikolai A. Podoltsev
Journal: Blood
Blood (2022) 140 (Supplement 1): 8921–8922.
https://doi.org/10.1182/blood-2022-165446
Published: 2022
Journal Articles

Impact of Allelic State on Overall Survival in TP53- mutant Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)

Jan Philipp Bewersdorf, Vanessa Hasle, Rory Michael Shallis, Ethan G. Thompson, Daniel Lopes de Menezes, Shelonitda Rose, Isaac W. Boss, Stephanie Halene, Torsten Haferlach, Brian Fox, Amer M. Zeidan
Journal: Blood
Blood (2022) 140 (Supplement 1): 8910–8911.
https://doi.org/10.1182/blood-2022-158592
Published: 2022
Journal Articles

A Multi-Center Phase Ib Trial of the Histone Deactylase Inhibitor (HDACi) Entinostat in Combination with Anti-PD1 Antibody Pembrolizumab in Patients with Refractory/Relapsed Myelodysplastic Syndromes (RR-MDS) or Oligoblastic Acute Myeloid Leukemia (RR-AML) after Hypomethylating Agent (HMA) Failure

Jan Philipp Bewersdorf, Rory Michael Shallis, Elad Sharon, Anne Caldwell, Wei Wei, Abdulraheem Yacoub, Yazan F. Madanat, Joshua F. Zeidner, Jessica K. Altman, Olatoyosi Odenike, Swaroopa Yerrabothala, Tibor Kovacsovics, Nikolai A. Podoltsev, Stephanie Halene, Richard F. Little, Richard Piekarz, Steven D. Gore, Tae Kon Kim, Amer M. Zeidan
Journal: Blood
Blood (2022) 140 (Supplement 1): 9084–9086.
https://doi.org/10.1182/blood-2022-158626
Published: 2022
Journal Articles

Clinical Outcomes of Patients with TP53 -Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Talha Badar, Ehab L. Atallah, Antoine N. Saliba, Rory Michael Shallis, Maximilian F. Stahl, Jan Philipp Bewersdorf, Guillerhme Sacchi De Camargo Correia, Anand Ashwin Patel, Yasmin Abaza, Guru Subramanian Guru Murthy, Adam S Duvall, Madelyn Burkart, Neil Palmisiano, Danielle Bradshaw, Vamsi K. Kota, Shira Dinner, Aaron D Goldberg, Mark R. Litzow
Journal: Blood
Blood (2022) 140 (Supplement 1): 6058–6060.
https://doi.org/10.1182/blood-2022-163795
Published: 2022
Journal Articles

Cost-Effectiveness of Azacitidine and Ivosidenib in Newly Diagnosed Older, Intensive Chemotherapy-Ineligible Patients with IDH1 -Mutant Acute Myeloid Leukemia

Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory Michael Shallis, Nikolai A. Podoltsev, Maximilian F. Stahl, Jessica M. Stempel, Eytan Stein, Scott F. Huntington, Amer M. Zeidan
Journal: Blood
Blood (2022) 140 (Supplement 1): 319–321.
https://doi.org/10.1182/blood-2022-158465
Published: 2022
Journal Articles

Real-World Practice Patterns and Outcomes Following Bruton Tyrosine Kinase Inhibitors (BTKi) in Older Patients with Mantle Cell Lymphoma (MCL): A Population-Based Analysis

Mengyang Di, Jessica B Long, Shalin K. Kothari, Tarsheen Sethi, Amer M. Zeidan, Nikolai A. Podoltsev, Rory Michael Shallis, Rong Wang, Jessica M. Stempel, Xiaomei Ma, Scott F. Huntington
Journal: Blood
Blood (2022) 140 (Supplement 1): 10904–10906.
https://doi.org/10.1182/blood-2022-164959
Published: 2022
Journal Articles

How Many Stratification Factors Are Reasonable and Can There be Too Many? Evaluation of Analysis Strategies in the Context of a Randomized Phase 2 Trial in Acute Myeloid Leukemia within the Myelomatch Platform

Anna Moseley, Boris Freidlin, Rory Michael Shallis, Amer M. Zeidan, David A. Sallman, Richard F. Little, Harry P. Erba, Michael L. Leblanc, Megan Othus
Journal: Blood
Blood (2022) 140 (Supplement 1): 8932–8933.
https://doi.org/10.1182/blood-2022-170376
Published: 2022
Journal Articles

Outcomes of Patients with Accelerated/Blast-Phase Myeloproliferative Neoplasms in the Current Era of Myeloid Therapies

Anand Ashwin Patel, James J. Yoon, Hannah Johnston, Evan C. Chen, Madelyn Burkart, Timothy Seijung Oh, Sunil G. Iyer, Ellen Madarang, Iyana Gross, Terrence Bradley, Yasmin Abaza, Jacqueline S. Garcia, Rory Michael Shallis, Guru Subramanian Guru Murthy, Vikas Gupta, Kristen M. Pettit, John Cursio, Olatoyosi Odenike
Journal: Blood
Blood (2022) 140 (Supplement 1): 6860–6862.
https://doi.org/10.1182/blood-2022-157603
Published: 2022
Journal Articles

Molecular, Epigenetic, and Immune Landscape of TP53- mutated (TP53-M) Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)

Jan Philipp Bewersdorf, Vanessa Hasle, Rory Michael Shallis, Ethan G. Thompson, Daniel Lopes de Menezes, Shelonitda Rose, Isaac W. Boss, Stephanie Halene, Torsten Haferlach, Brian Fox, Amer M. Zeidan
Journal: Blood
Blood (2022) 140 (Supplement 1): 6247–6249.
https://doi.org/10.1182/blood-2022-156460
Published: 2022
Journal Articles

Outcomes of Adults Treated with a Hypomethylating Agent Plus Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia: A Multicenter Retrospective Study

Emily Geramita, Hong Wang, Melissa Bastacky, Jessica Cohen, Rory Michael Shallis, Talha Badar, Mark R. Litzow, Annie Im
Journal: Blood
Blood (2022) 140 (Supplement 1): 6187–6188.
https://doi.org/10.1182/blood-2022-170647
Published: 2022